Navigation Links
Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
Date:5/7/2012

MARLBOROUGH, Mass., May 7, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology will be highlighted both as part of the scientific sessions and during a private academic symposium at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston, MA. The presentations will feature clinical experiences and outcomes using the company's technology, the first visually-guided laser balloon ablation system.

"We are pleased that over two years of comprehensive clinical experiences with our technology will be featured at this prominent industry conference. Many of the leading international experts in heart rhythm management will be participating in these sessions and presenting their own findings with the HeartLight EAS, and we anticipate engaging discussion on the applicability of the system in clinical practice," said Stephen Sagon, President and CEO of CardioFocus.

During the scientific sessions, the presentation "Worldwide Experience Using the Endoscopic Ablation System for Ablation of Atrial Fibrillation" will give an overview of the feasibility and safety of AF ablation using the HeartLight EAS, with findings representing the first patients treated with the technology by 32 different operators across 19 medical centers. The presentation will be made by Boris Schmidt, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany on Friday, May 11 at 3:25 p.m. ET.

The HeartLight EAS Symposium, to be held the evening of Thursday, May 10 at the Renaissance Boston Waterfront Hotel, will feature presentations from cardiology thought leaders on the evolution of pulmonary vein (PV) isolation ablation, the adoption of the new visually-guided laser balloon ablation technique, and the clinical experiences with the technology at centers throughout Europe. It will be chaired by Prof. Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic and Prof. Thorsten Lewalter, MD, of Isar Heart Center, Munich, Germany.

The HeartLight EAS is a unique catheter ablation technology that incorporates an endoscope for direct visualization of the inside of the heart and a compliant, dynamically adjustable balloon catheter designed for improved contact with the PV ostium irrespective of the individual patient anatomy. It also utilizes laser energy for more efficient, durable and precise ablation treatment. 

The system is available in Europe for the treatment of AF, and is currently the focus of a pivotal trial in the U.S. For more information, please visit the CardioFocus booth #1103 or www.CardioFocus.com.

About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight® Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., and currently the focus of a pivotal trial initiated in 2012. CardioFocus is headquartered in Marlborough, MA, USA.  For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.Company Contact:

Media Contact:Anjie Roldan

Lisa CookVice President Finance

(646) 536-7012(508) 658-7237

lcook@theruthgroup.com aroldan@cardiofocus.com
'/>"/>

SOURCE CardioFocus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telemedicine Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
2. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
3. Leading Pharma Events CPhI Worldwide, ICSE, P-MEC Europe & InnoPack to Return to Frankfurt in 2013 after Record Breaking Year
4. Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
5. Cardica Achieves Key Milestone With Over 25,000 PAS-Port® Proximal Anastomosis Systems Deployed Worldwide
6. UH Case Medical Center the First in Region to Enroll Patients in Worldwide Study
7. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
8. The Outlook for Medical Devices Worldwide
9. The Outlook for Pharmaceuticals Worldwide
10. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
11. Medical Centers Worldwide Adopt Both Accurays CyberKnife and TomoTherapy Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):